The objectives of this project are to: (1) analyze the neutral glycosphingolipids and gangliosides from the leukocytes of normal donors and leukemic patients; (2) find a human leukemia cell line(s) to use as a model system to evaluate the regulation of neutral glycosphingolipids in human leukocytes; and (3) determine if the glycosphingolipids of human leukocytes are I,i antigens. We have completed structural characterization of the neutral glycosphingolipids and gangliosides of normal human leukocytes and leukemia cells. These studies have demonstrated that mature human leukocytes can be distinguished on the basis of their neutral glycosphingolipids (i.e., myeloid cells express neolacto compounds and lymphoid cells express globo compounds). We have also found that immature cells express both globo and neolacto compounds, suggesting a relationship between cell differentiation and glycolipid expression. We have evaluated the distribution of GD?3? ganglioside among human leukocytes using an anti-GD?3? monoclonal antibody and found that normal Ieukocytes and CML cells do not express this compound, whereas all other types of leukemic leukocytes have GD?3?. Therefore, GD?3? appears to be restricted in its distribution to leukemic blast cells and chronic lymphocytic cells. Glycolipids carrying the i-antigen have been purified from CML cells and structurally characterized and detected by immunostaining with anti-i antibodies. We have purified ?14?C-galactose-labeled glycolipids from three myeloid leukemic cell lines and have structurally characterized them using glycosidases and HPLC of their perbenzolylated derivatives. The results of these analyses demonstrate that alterations in neutral glycosphingolipid expression occur after the myeloblastic stage of differentiation and before or at the promyelocyte stage. A comparison of the glycosphingolipids synthesized by untreated cells and cells treated with differentiating agents (butyrate, dimethyl sulfoxide, and phorbol diesters) will be made. The results from these studies will be useful in determining if there are variations in the classes of glycolipids synthesized by different leukemic cells and if chemically induced differentiation leads to alterations in glycolipid biosynthesis that are related to those occurring in freshly isolated leukocytes. (MI)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA032826-04
Application #
3170654
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1982-08-01
Project End
1988-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
de Vries, T; Srnka, C A; Palcic, M M et al. (1995) Acceptor specificity of different length constructs of human recombinant alpha 1,3/4-fucosyltransferases. Replacement of the stem region and the transmembrane domain of fucosyltransferase V by protein A results in an enzyme with GDP-fucose hydrolyzing act J Biol Chem 270:8712-22
Holmes, E H; Xu, Z; Sherwood, A L et al. (1995) Structure-function analysis of human alpha 1-->3fucosyltransferases. A GDP-fucose-protected, N-ethylmaleimide-sensitive site in FucT-III and FucT-V corresponds to Ser178 in FucT-IV. J Biol Chem 270:8145-51
Robinson, N E; de Vries, T; Davis, R E et al. (1994) Expression of fucosylated antigens and alpha 1,3 fucosyltransferases in human leukaemia cell lines. Glycobiology 4:317-26
Hu, J; Stults, C L; Holmes, E H et al. (1994) Structural characterization of intermediates in the biosynthetic pathway of neolacto glycosphingolipids: differential expression in human leukaemia cells. Glycobiology 4:251-7
Stults, C L; Sullivan, M T; Macher, B A et al. (1994) Analysis of glycosphingolipid glycosyltransferase products on TLC plates by combined storage phosphor and immunostaining techniques. Anal Biochem 219:61-70
Holmes, E H; Macher, B A (1993) Specificity of fucose transfer to GlcNAc residues of extended chain neolacto-series glycolipids catalyzed by human alpha 1-->3fucosyltransferases: effect of the lipidic environment on the myeloid enzyme form. Arch Biochem Biophys 301:190-9
Stults, C L; Macher, B A (1993) Beta 1-3-N-acetylglucosaminyltransferase in human leukocytes: properties and role in regulating neolacto glycosphingolipid biosynthesis. Arch Biochem Biophys 303:125-33
Lowe, J B; Kukowska-Latallo, J F; Nair, R P et al. (1991) Molecular cloning of a human fucosyltransferase gene that determines expression of the Lewis x and VIM-2 epitopes but not ELAM-1-dependent cell adhesion. J Biol Chem 266:17467-77
Macher, B A; Holmes, E H; Swiedler, S J et al. (1991) Human alpha 1-3 fucosyltransferases. Glycobiology 1:577-84
Corral, L; Singer, M S; Macher, B A et al. (1990) Requirement for sialic acid on neutrophils in a GMP-140 (PADGEM) mediated adhesive interaction with activated platelets. Biochem Biophys Res Commun 172:1349-56

Showing the most recent 10 out of 23 publications